Enact Reports Fourth Quarter and Full Year 2023 Results
_______________________________________
Fourth quarter GAAP Net Income of $157 million, or $0.98 per diluted share
Full year GAAP Net Income of $666 million, or $4.11 per diluted share
Fourth quarter Adjusted Operating Income of $158 million, or $0.98 per diluted share
Full year Adjusted Operating Income of $676 million, or $4.18 per diluted share
Fourth quarter Return on Equity of 13.8% and Adjusted Operating Return on Equity of 13.9%
Full year Return on Equity of 15.2% and Adjusted Operating Return on Equity of 15.5%
Record Primary insurance in-force of $263 billion, a 6% increase from fourth quarter 2022
PMIERs Sufficiency of 161% or $1,887 million
Returned over $300 million of capital to shareholders in 2023
Book Value Per Share of $29.07 and Book Value Per Share excluding AOCI of $30.52
Related news for (ACT)
- Actuate Therapeutics Reports Positive Biomarker and Machine Learning Data from Phase 2 Elraglusib Trial in First-Line Treatment of Metastatic Pancreatic Cancer at ASCO
- Actuate Therapeutics Announces Inclusion in the Russell 3000® and Russell 2000® Indexes
- Actuate Therapeutics Shares Highlights from KOL Event on Positive Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
- Actuate Therapeutics Presents Topline Elraglusib Phase 2 Data at ASCO 2025 Annual Meeting: Trial Meets Primary Endpoint of Median Overall Survival and Doubles 1-Year Survival in First-Line Treatment of Metastatic Pancreatic Cancer
- Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer
